<DOC>
	<DOCNO>NCT00087022</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . It yet know whether monoclonal antibody therapy effective treat kidney cancer . PURPOSE : This randomized phase III trial study monoclonal antibody therapy see well work treat patient undergone surgery nonmetastatic primary kidney cancer .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy ( Rencarex® ) Treating Patients Who Have Undergone Surgery Non-metastatic Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate disease-free overall survival patient primary clear cell renal cell carcinoma high risk recurrence treat chimeric monoclonal antibody cG250 ( WX-G250 ) v placebo adjuvant setting . Secondary - Evaluate safety drug patient . - Assess quality life patient treated drug . - Perform pharmacokinetic analysis WX-G250 . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord risk criterion participate center ( US v Non-US ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive monoclonal chimeric antibody cG250 ( WX-G250 ) IV 15 minute weekly 24 week . - Arm II : Patients receive placebo IV 15 minute weekly 24 week . In arm , treatment continue absence disease progression unacceptable toxicity . Blood sample collect pharmacokinetic analysis . Quality life assess baseline , week 12 24 treatment , 6 month completion study treatment . Patients follow every 3 month year 1 2 , every 6 month year 3 4 , annually year 5 thereafter . PROJECTED ACCRUAL : A total 864 patient expect 856 ( 428 per treatment arm ) accrue trial .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary clear cell renal cell carcinoma Meets 1 follow high risk criterion : T3a , N0/NX , M0 OR T3b , N0/NX , M0 OR T3c , N0/NX , M0 OR T4 , N0/NX , M0 Any T stage N + disease M0 T1b , N0/NX , M0 OR T2 , N0/NX , M0 , grade ≥ 3 ( Fuhrman nuclear grade system least 3 grade ) Prior nephrectomy ( total partial ) primary renal cell carcinoma document clear cell histology within past 12 week No evidence macroscopic microscopic residual disease PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 01 Life expectancy Not specify Hematopoietic Platelet count &gt; 100,000/mm^3 WBC &gt; 3,000/mm^3 Hemoglobin &gt; 10 g/dL Hepatic AST ALT &lt; 3 time upper limit normal ( ULN ) Bilirubin &lt; 1.5 time ULN Hepatitis B surface antigen ( HbsAg ) negative Hepatitis C antibody negative Renal Creatinine &lt; 2.0 time ULN Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV I II negative No concurrent unrelated illness significantly jeopardize patient ' clinical status No active infection No inflammation No medical condition laboratory abnormality would preclude study participation No malignancy within past 5 year except surgically cure nonmelanoma skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy More 5 year since prior immunotherapy No prior murine chimeric antibody therapy Chemotherapy More 5 year since prior chemotherapy Endocrine therapy No concurrent corticosteroid Cushing dose another disease Physiologic corticosteroid replacement therapy allow discretion primary investigator Radiotherapy More 5 year since prior radiotherapy Surgery See Disease Characteristics No prior organ transplantation Other No concurrent immunosuppressive agent ( e.g. , cyclosporine tacrolimus )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>clear cell renal cell carcinoma</keyword>
	<keyword>stage I renal cell cancer</keyword>
	<keyword>stage II renal cell cancer</keyword>
	<keyword>stage III renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
</DOC>